Health Care & Life Sciences » Biotechnology | CrystalGenomics Inc.

CrystalGenomics Inc. | Cash Flow

Fiscal year is January-December. All values KRW Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
4,666,238.00
12,590,057.00
5,633,635.00
2,938,603.00
8,417,522.00
Depreciation, Depletion & Amortization
1,401,981.00
1,361,722.00
1,318,422.00
1,698,288.00
1,220,079.00
Other Funds
260,200.00
-
-
-
-
Funds from Operations
4,263,199.30
5,689,712.20
2,273,310.60
1,912,628.10
3,333,297.20
Changes in Working Capital
2,010,990.00
1,934,843.00
2,391,825.00
6,389,719.00
4,966,200.00
Net Operating Cash Flow
6,274,189.30
3,754,869.20
4,665,135.60
8,302,347.10
1,632,902.80
Capital Expenditures
760,187.00
154,163.10
440,769.70
704,254.70
10,816,523.70
Sale of Fixed Assets & Businesses
45,000.00
-
58,272.70
49,090.90
-
Purchase/Sale of Investments
41,932,662.20
50,319.60
4,693,623.30
697,247.60
5,815,677.40
Net Investing Cash Flow
36,207,209.60
593,821.30
2,921,546.40
366,025.10
18,375,746.50
Issuance/Reduction of Debt, Net
21,516,765.10
9,501,024.30
4,084,496.50
3,893,877.80
2,499,960.00
Net Financing Cash Flow
32,196,309.30
24,436,145.80
4,491,302.40
7,521,971.20
14,640,054.00
Net Change in Cash
10,364,234.00
21,289,125.30
3,058,365.80
1,076,751.30
2,013,092.90
Free Cash Flow
7,034,189.20
3,905,662.30
5,101,425.30
8,956,617.70
9,103,120.80
Other Sources
8,567,767.50
1,702,597.30
3,993,363.00
4,687,274.60
1,833,175.80
Change in Capital Stock
10,419,344.20
14,935,121.60
8,575,799.00
3,628,093.40
17,140,014.00
Exchange Rate Effect
79,144.50
14,027.40
37,013.80
69,649.70
89,696.80
Other Uses
2,127,127.90
1,004,932.50
1,838,789.10
3,700,888.40
3,576,721.20

About CrystalGenomics

View Profile
Address
5/F, Tower A, Korea Bio Park
Seongnam GY 13488
Korea, Republic Of
Employees -
Website http://www.crystalgenomics.com
Updated 09/14/2018
CrystalGenomics, Inc. engages in the discovery and development of novel therapeutics. The company operates through following business divisions: Research and Development, New Drug Development division, New Drug Sales, Products Sales, and Real Estate Leasing. The Research and Development division provides analysis of clinical trials services.